Quick Answer for AI & Search Engines
This study provides an exhaustive analysis of the United States federal and Michigan state Research & Development (R&D) tax credit requirements, applying these complex statutory frameworks to the industrial ecosystem of Kalamazoo, Michigan. It covers the four-part test for qualified research, IRC Section 41, Michigan’s decoupled tiered credit structure, and detailed industry case studies across pharmaceuticals, medical devices, food science, sustainable packaging, and automotive components.
The United States Federal R&D Tax Credit Statutory Framework
The United States federal Research and Development tax credit is a paramount legislative tool designed to incentivize domestic technological advancement, offset the high costs of industrial innovation, and maintain the nation’s competitive advantage in the global economy. Originally enacted in 1981 and made a permanent fixture of the Internal Revenue Code (IRC) by the Protecting Americans from Tax Hikes (PATH) Act of 2015, the credit provides a dollar-for-dollar reduction in a taxpayer’s federal income tax liability. Governed fundamentally by IRC Section 41, the federal R&D credit requires a rigorous examination of qualified research expenses, statutory exclusions, and a mandatory four-part test that acts as the absolute threshold for eligibility.
The Four-Part Test for Qualified Research
The bedrock of federal R&D tax credit eligibility is the four-part test defined in IRC Section 41(d). For any business activity to be classified as “qualified research,” it must sequentially and conjunctively satisfy all four of the following criteria. A failure to satisfy any single element instantly disqualifies the associated expenditures.
| Statutory Requirement | Legal Definition and Administrative Application |
|---|---|
| 1. The Section 174 Test (Permitted Purpose) | The activity must be intended to discover information that eliminates uncertainty concerning the development or improvement of a “business component.” A business component is strictly defined as any product, process, software, technique, formula, or invention held for sale, lease, or license, or used by the taxpayer in a trade or business. The improvement must relate fundamentally to functionality, performance, reliability, or quality, rather than mere cosmetic or aesthetic enhancements. |
| 2. The Discovering Technological Information Test | The process of experimentation utilized to eliminate the uncertainty must fundamentally rely on principles of the “hard sciences.” Acceptable disciplines include the physical sciences (e.g., physics, chemistry), biological and life sciences, computer science, or engineering. Research based on economics, humanities, psychology, or the social sciences is explicitly excluded from eligibility by statute. |
| 3. The Elimination of Technical Uncertainty | At the commencement of the research project, there must exist a verifiable and objective uncertainty regarding the taxpayer’s capability to develop the component, the method or process by which the component should be developed, or the appropriate design of the component. If the solution is known or readily available to competent professionals in the field at the project’s outset, no technical uncertainty exists. |
| 4. The Process of Experimentation Test | The taxpayer must engage in a systematic, iterative process designed to evaluate one or more alternatives to achieve the desired result. This involves formulating a hypothesis, conducting testing (through mathematical modeling, computer simulation, or systematic trial and error), analyzing the results, and refining the hypothesis based on that analysis. Standard, routine engineering practices that lack this iterative evaluation of alternatives do not satisfy this requirement. |
Qualified Research Expenses (QREs)
Upon satisfying the four-part test, taxpayers must identify and calculate their Qualified Research Expenses (QREs) pursuant to IRC Section 41(b). If an expense is not explicitly permitted under this section, it cannot be claimed. QREs are categorized into three primary statutory pools:
- In-House Wages: This category comprises taxable wages, as defined in IRC Section 3401(a), paid or incurred to an employee for performing “qualified services”. This definition includes standard salaries, bonuses, and stock option redemptions that are subject to withholding. Importantly, qualified services encompass not only the direct performance of research (e.g., a laboratory scientist or software engineer) but also the direct supervision of research and the direct support of research (e.g., a technician cleaning equipment or machining a prototype).
- In-House Supplies: Under Section 41(b)(2), taxpayers may claim amounts paid or incurred for tangible supplies used or consumed directly in the conduct of qualified research. This includes raw materials used in prototype fabrication, test batches, and clinical trial supplies. By statutory definition, supplies exclude land, improvements to land, and depreciable property (such as the machinery or manufacturing equipment itself).
- Contract Research Expenses: When a taxpayer engages a third party to perform research on its behalf, 65% of the amount paid or incurred is generally eligible as a QRE. The limitation accounts for the assumption that the remaining 35% covers the contractor’s overhead and profit margins, which are ineligible. This allowance increases to 75% if the amounts are paid to a “qualified research consortium,” defined under Section 41(b)(3)(C) as a tax-exempt organization (under Section 501(c)(3) or 501(c)(6)) organized and operated primarily to conduct scientific research.
Statutory Exclusions to Qualified Research
Congress deliberately established parameters to prevent the credit from subsidizing routine business operations. Under IRC Section 41(d)(4), several activities are explicitly excluded from the definition of qualified research, regardless of whether they appear to meet the four-part test.
The exclusion for “research after commercial production” bars activities conducted once a product meets its basic design specifications and is ready for commercial sale or use. The exclusion for “adaptation” prevents taxpayers from claiming expenses incurred while modifying an existing business component to meet a specific customer’s requirement. “Duplication” exclusions prohibit claims related to reproducing an existing component from a physical examination, plans, blueprints, or detailed specifications (reverse engineering). Other notable exclusions include routine data collection, efficiency surveys, management studies, market research, routine quality control testing, and any research conducted outside the United States, Puerto Rico, or a possession of the United States.
Critically, the statute mandates an exclusion for “funded research”. If a taxpayer’s research is funded by a grant, contract, or another person or governmental entity, it is disqualified. To overcome the funded research exclusion, the taxpayer must demonstrate that payment for the research is entirely contingent on the success of the research (retaining the economic risk of failure) and that the taxpayer retains substantial rights to the intellectual property developed.
The Intersection of IRC Section 41 and Section 174
The administration of the Section 41 R&D credit is inextricably linked to the treatment of Research and Experimental (R&E) expenditures under IRC Section 174. Historically, Section 174 allowed taxpayers to immediately deduct 100% of their R&E costs in the tax year they were incurred, providing significant upfront cash flow to innovative enterprises.
However, a highly consequential provision within the Tax Cuts and Jobs Act (TCJA) of 2017 radically altered this dynamic. Effective for tax years beginning after December 31, 2021, the TCJA eliminated the immediate expensing option. Instead, taxpayers are now mandated to capitalize and amortize all domestic R&E expenditures ratably over a 5-year period (and over a 15-year period for foreign research). This legislative shift dramatically increased the immediate tax burden on research-intensive companies, effectively making innovation more expensive and reducing the capital available for reinvestment.
Because the Section 41 R&D credit eligibility requires that an expense “may be treated as” a specified R&E expenditure under Section 174, the alignment of these two statutes requires meticulous accounting. The legislative landscape remains volatile. Proposed legislation, such as the “One Big Beautiful Bill Act” (P.L. 119-21), contains provisions to add a new Section 174A to the code, which would allow taxpayers to revert to immediate deduction of domestic R&E expenditures for tax years beginning after December 31, 2024, or elect to capitalize and amortize over 60 months. Taxpayers navigating this transition must also consider the implications of Section 280C elections, which require taxpayers to reduce their Section 174 deduction by the amount of the Section 41 credit claimed, or alternatively, elect a reduced R&D credit to preserve the full deduction.
IRS Audit Techniques, Substantiation, and Recent Case Law
The Internal Revenue Service (IRS) administers the R&D tax credit with rigorous scrutiny, guided by specialized Audit Techniques Guides (ATGs) and recent legal precedents established by the United States Tax Court. Taxpayers must maintain contemporaneous documentation that bridges the gap between the expenditures claimed and the technical uncertainties resolved.
IRS Audit Techniques Guides (ATGs) and Directives
To assist examiners, the IRS Large Business & International (LB&I) Division publishes industry-specific ATGs that detail standard examination procedures, common issues, and the appropriate evaluation of evidence.
In the manufacturing sector, examiners are instructed to request project authorizations, budgets, work orders, progress studies, field and lab verification data, and complete copies of third-party contracts. The IRS favors “project tracking” methodologies over simple “cost center” allocations, as project tracking directly connects the expense to its technological purpose.
The IRS has also issued a specific ATG and a 2012 LB&I Directive regarding the Pharmaceutical and Biotechnology industries. This guidance explicitly breaks down the drug development process into four stages: Discovery/Preclinical, Clinical Development (Phases I-III), Regulatory Review, and Post-Marketing. The directive establishes risk profiles, noting that activities in the discovery and clinical phases are generally low-risk (likely to qualify), while post-marketing activities are high-risk (unlikely to qualify) due to the commercial production exclusion.
For compliance, taxpayers face increasingly stringent reporting mandates. Following Chief Counsel Memorandum (CCM) Number 20214101F, the IRS revised Form 6765 (Credit for Increasing Research Activities). The newly added Section G requires taxpayers to provide detailed information broken down by specific business component, identifying all research activities performed, the individuals performing them, and the specific technological information sought.
Jurisprudential Analysis: Recent Tax Court Decisions
The interpretation of IRC Section 41 is continually refined through federal litigation. Recent Tax Court and appellate decisions underscore the immense evidentiary burden placed on the taxpayer and clarify nuanced statutory concepts such as the “process of experimentation,” the “shrink-back rule,” and the “funded research” exclusion.
| Case Precedent | Core Legal Issue Analyzed | Court Findings and Practical Implications |
|---|---|---|
| Phoenix Design Group, Inc. v. Commissioner (T.C. Memo 2024-113) | Process of Experimentation & Documentation Standard | The taxpayer, a mechanical, electrical, and plumbing (MEPF) engineering firm, claimed credits based on a standard six-stage design process. The Tax Court ruled in favor of the IRS, asserting that standard engineering oversight does not constitute a “process of experimentation” without evidence of hypothesis testing and evaluation of alternatives. The court imposed a 20% accuracy-related penalty due to the taxpayer treating projects generically and failing to maintain contemporaneous, subcomponent-level documentation. |
| Little Sandy Coal Company, Inc. v. Commissioner | The Shrink-Back Rule & Allocation Methodologies | The court denied credits because the taxpayer claimed an entire massive vessel as the business component. The court emphasized the “shrink-back rule,” stating that if the overall component does not meet the four-part test, the taxpayer must shrink back to the specific subcomponent (e.g., a novel hull design or propulsion system) where the technical uncertainty actually resided. The taxpayer failed to provide granular time and activity data to support this allocation. |
| George v. Commissioner (T.C. Memo. 2026-10) | Biological Uncertainty & Agricultural Innovation | In a highly taxpayer-friendly ruling, the Tax Court forcefully acknowledged that modern agriculture involves complex biological systems, evolving disease pressures, and intricate chemistry. The court validated that overcoming biological uncertainties in agricultural production constitutes legitimate technological experimentation, providing a roadmap for agribusiness and life sciences companies to claim the credit. |
| System Technologies v. Commissioner | State-Level Contract Law & Funded Research | In evaluating whether custom manufacturing contracts were “funded” (and thus excluded under Section 41(d)(4)(H)), the court closely examined the choice-of-law provisions designating Indiana state law. The ruling reinforced that state-level legal protections and contract structures dictate who bears the economic risk of failure and who owns the intellectual property, determining federal tax eligibility. |
| Meyer, Borgman & Johnson, Inc. v. Commissioner (No. 23-1523, 8th Cir. 2024) | Economic Risk in Professional Services Contracts | The 8th Circuit Court of Appeals affirmed the denial of credits to a structural engineering firm. The taxpayer argued payment was contingent on producing designs that met code requirements. The court disagreed, ruling that while the contracts involved economic risk regarding the cost of performance (e.g., fixed-fee overruns), payment was not contingent on the success of the underlying research itself, thereby rendering the research funded. |
| Smith v. Commissioner | Foreign Law Application & Intellectual Property Rights | The Tax Court evaluated architectural research contracts governed by the laws of Dubai and the UAE. The court found that foreign law automatically granted copyright and reproduction rights to the creators, satisfying the requirement that the taxpayer retain substantial rights to the research results. The court also clarified that partners’ self-employment income can be considered a QRE under former IRC Section 174(e). |
The Michigan State R&D Tax Credit Framework
Recognizing that the federal Section 174 amortization mandates threatened local innovation capital, and seeking to reposition the state as a dominant hub for technological advancement and job creation, Michigan recently enacted a powerful, standalone R&D tax incentive. For the first time in over a decade—following the expiration of the Single Business Tax (SBT) and Michigan Business Tax (MBT) legacy credits—Michigan offers a dedicated R&D credit.
Created by House Bills 5100 (Public Act 186 of 2024) and 5101 (Public Act 187 of 2024), signed by Governor Gretchen Whitmer in January 2025, the new Michigan R&D tax credit provides financial incentives for corporate income tax (CIT) taxpayers and certain flow-through entities. The credit applies to basic research, applied research, and experimental development activities conducted physically within the borders of Michigan, effective for tax years beginning on or after January 1, 2025.
Base Amount Calculation and Tiered Credit Structure
The Michigan legislation explicitly relies on the federal IRC Section 41 definition of “qualified research expenses,” establishing a unified conceptual framework for what activities and costs qualify. However, the state deviates significantly from the federal model in its calculation of the base amount and its establishment of taxpayer tiers.
Michigan calculates the base amount as the average annual QRE for the three years strictly preceding the credit year. This methodology contrasts sharply with the federal Alternative Simplified Credit (ASC) method, which bases its calculation on 50% of the average QREs for the prior three tax years. Furthermore, the state has decoupled entirely from the federal IRC Section 174 amortization rules, allowing businesses to claim the Michigan credit based on their full, unamortized QREs incurred within the state, offering crucial cash flow relief.
To protect state revenue while aggressively supporting startups and mid-market innovators, the Michigan R&D credit establishes two distinct tiers based on the total number of individuals employed by the taxpayer, measured as defined under IRC Section 3401(c).
| Taxpayer Classification | Defined Employee Headcount | Credit on QREs Up To Base Amount | Credit on QREs Exceeding Base Amount | Maximum Annual Credit Cap per Entity |
|---|---|---|---|---|
| Small Business | Fewer than 250 employees | 3% | 15% | $250,000 |
| Large Business | 250 or more employees | 3% | 10% | $2,000,000 |
Additional Incentives: Taxpayers who enter into a formal, written collaborative agreement with a research university located within Michigan may be eligible for an additional credit equal to 5% of their QREs that exceed the base amount, capped at a maximum of $200,000 per taxpayer.
Statutory Caps, Tentative Claims, and Proration Mechanics
The most critical administrative feature of the Michigan R&D credit is the imposition of a hard statewide annual cap of $100 million. This cap is bifurcated, allocating $75 million for large taxpayers and $25 million for small taxpayers.
Because the credit is capped, the Michigan Department of Treasury requires all eligible taxpayers to file an advance “tentative claim” through Michigan Treasury Online (MTO). This claim must represent the “unadjusted credit amount” calculated using actual, not estimated, expenses incurred during the calendar year.
For R&D expenses incurred during the inaugural 2025 calendar year, all claimants—regardless of whether they are calendar-year or fiscal-year CIT taxpayers, or flow-through entities filing withholding tax returns—must submit their tentative claims no later than the absolute statutory deadline of April 1, 2026. No extensions are permitted, and tentative claims will not be accepted after this date. For all subsequent calendar years (e.g., 2026 expenses), this deadline accelerates to March 15 (e.g., March 15, 2027).
Following the deadline, the Treasury aggregates all tentative claims. If the total exceeds the $100 million cap, statutory proration provisions are triggered. The Treasury will then issue “tentative claim adjustment notices” to all claimants, dictating the pro-rated amount they are legally permitted to claim on their final annual tax returns. Unitary Business Groups (UBGs) must calculate their eligibility and base amounts collectively, as the UBG is considered the single taxpayer under the Michigan Corporate Income Tax (MCL 206.611).
Kalamazoo’s Industrial Heritage and the Ecosystem of Innovation
To accurately analyze the application of federal and state R&D tax credits in Kalamazoo, Michigan, it is essential to understand the unique historical forces and geographic advantages that birthed its highly diversified, modern industrial base. Located in Southwest Michigan, Kalamazoo was settled in 1829 and incorporated as a village in 1843.
The region’s initial economic power was derived from its natural resources. The Kalamazoo River provided a massive, reliable source of water, while the surrounding timber forests offered raw materials. Furthermore, the area featured highly organic, fertile muckland formed by glacial retreat. By the late 19th century, Dutch immigrants leveraged this muckland to cultivate enormous quantities of celery, earning Kalamazoo the nickname “The Celery City”. This deep agricultural expertise subsequently facilitated the rise of sophisticated botanical extraction and flavor chemistry industries.
Simultaneously, leveraging the water and timber, Kalamazoo evolved into “The Paper City”. Beginning with the Kalamazoo Paper Company in 1867, the valley assembled the world’s largest concentration of paper mills by the early 20th century, employing half the local workforce and establishing a legacy of complex mechanical and chemical engineering.
As the 20th century progressed, the city’s manufacturing capabilities diversified dramatically. The skilled mechanics and craftsmen originally employed by carriage and wagon makers like the Michigan Buggy Company (which produced 47,000 units in 1887) transitioned seamlessly into the automotive and heavy machinery sectors. Companies like the Barley Motor Car Company and Checker Motors Corporation (which relocated to Kalamazoo in 1923 to mass-produce the iconic New York City taxicabs) anchored a massive metalworking and component manufacturing base. The city also supported unique precision manufacturing operations, such as the Shakespeare Company (fishing tackle) and Gibson Guitar Company, which was founded in Kalamazoo by Orville Gibson in the 1890s.
This historical convergence of agricultural science, chemical processing (paper), and precision mechanical engineering forged a “crucible of innovation”. Today, the Kalamazoo-Portage metropolitan area is a major economic engine, boasting a population of over 261,000 and serving as the headquarters or major operational hub for twenty different Fortune 1000 companies. The legacy industries have evolved into highly advanced sectors, including a 150-year life sciences legacy, one of the nation’s most robust medical device groupings, and cutting-edge aerospace and automotive component development.
Exhaustive Industry Case Studies in Kalamazoo, Michigan
The following five case studies dissect the historical genesis of specific industries within Kalamazoo. By applying the statutory requirements of the United States federal R&D tax credit (IRC Section 41) and the Michigan state R&D tax credit (PA 186 and 187 of 2024), alongside IRS administrative guidance and Tax Court jurisprudence, these case studies evaluate how modern enterprises within these sectors can optimize their tax credit claims.
Pharmaceuticals and Life Sciences (The Legacy of Upjohn)
Historical Development in Kalamazoo The foundation of Kalamazoo’s 150-year life sciences legacy was laid in 1886 by Dr. William E. Upjohn. Practicing medicine in nearby Hastings, Michigan, Dr. Upjohn observed that existing medicinal pills were often so hard and insoluble that they passed through patients’ digestive tracts without releasing their therapeutic compounds. Driven by the “impulse to produce something better adapted to the use of the country physician,” he invented a revolutionary method to manufacture “friable pills,” which could be easily crushed into powder and absorbed by the body. To market his invention, he famously mailed wooden planks to doctors with a rival’s pill and his own, instructing them to hammer the pills into the wood.
Seeking better rail infrastructure for distribution, Dr. Upjohn relocated his operations to Kalamazoo, founding The Upjohn Company. Throughout the 20th century, Upjohn pioneered massive pharmacological breakthroughs, including the bioconversion of steroid intermediates and the synthesis of cortisone in the 1950s. In 1992, Upjohn was acquired by Pharmacia, which subsequently merged with Monsanto, and was ultimately acquired by Pfizer in 2002. Today, Kalamazoo remains a global epicenter for pharmaceutical manufacturing, highlighted by the massive local production of Pfizer’s COVID-19 vaccine.
Application of R&D Tax Credit Laws Modern pharmaceutical and biotechnology enterprises operating in Kalamazoo engage in highly capital-intensive research that aligns perfectly with the statutory intent of IRC Section 41. The IRS Large Business & International (LB&I) Directive on Pharmaceutical Drugs and Therapeutic Biologics provides specific guidance, defining the development process in four stages: Discovery and Preclinical, Clinical Development (Phases I-III), Regulatory Review, and Post-Marketing.
Research activities conducted during the Discovery and Clinical phases are classified by the IRS as low-risk for audit adjustment, meaning they inherently satisfy the four-part test. Designing new therapeutics, developing improved drug delivery mechanisms, and conducting safety and pharmacokinetics trials directly address profound technological uncertainties.
Qualified Research Expenses (QREs) in this sector are extensive. Wages paid to analytical scientists, formulation chemists, clinical trial managers, pharmacology associates, and QA/QC specialists directly performing or supervising the research are prime QREs. Furthermore, the massive costs of biological supplies consumed during animal tissue testing, early-stage formulation batches, and clinical trial supplies are fully eligible. Contract research expenses paid to external Contract Research Organizations (CROs) to conduct specialized laboratory testing also qualify, generally calculated at 65% of the invoiced amount. However, taxpayers must carefully exclude all “Post-Marketing” research activities, as these trigger the IRC Section 41(d)(4) exclusion for research conducted after the beginning of commercial production.
Michigan State Credit Application: A large pharmaceutical manufacturer in Kalamazoo with thousands of global employees definitively falls under Michigan’s “large business” tier. If this entity averages $50 million in Michigan-specific QREs over the 2022-2024 period (the base amount) and incurs $70 million in QREs in the 2025 calendar year, the calculation under Michigan law is highly lucrative. They would earn a 3% credit on the first $50 million ($1,500,000) and a 10% credit on the $20 million excess ($2,000,000), totaling $3,500,000. However, because this exceeds the statutory large taxpayer cap, their final state credit would be limited to the maximum $2,000,000 per year, subject to the $100 million statewide proration.
Medical Device Manufacturing (The Legacy of Stryker)
Historical Development in Kalamazoo Kalamazoo’s status as one of the most robust medical device groupings in the United States is primarily attributed to Dr. Homer Stryker. Following a brief stint at a private hospital, Dr. Stryker opened a general medical practice in downtown Kalamazoo in 1928, serving as the Kalamazoo County physician. Seeking to specialize, he returned to the University Hospital in Ann Arbor to complete a residency in orthopedic surgery.
Upon his return to Kalamazoo in 1939, Dr. Stryker realized that existing orthopedic tools and patient handling equipment were fundamentally inadequate. Guided by his foundational philosophy, “If your tools don’t work, make them work,” he began inventing solutions. He invented the turning bed frame to prevent bedsores in immobile patients, the walking heel to aid mobility, and the revolutionary oscillating cast saw, which cut through hard plaster casts without damaging the underlying soft tissue. In 1941, he established the Orthopedic Frame Company, which was later renamed Stryker Corporation. Kalamazoo provided an ideal incubator for this enterprise; the local workforce possessed immense expertise in precision metal stamping and tooling, developed through the buggy and automotive industries (such as Checker Motors). Today, Stryker is a multinational medical technologies corporation generating over $22 billion in revenue, maintaining its global headquarters in Kalamazoo and anchoring a massive regional supply chain of contract manufacturers.
Application of R&D Tax Credit Laws Medical device manufacturing relies heavily on the “process of experimentation” test under IRC Section 41. Innovation in this sector encompasses both the development of novel medical products and the complex manufacturing processes required to produce them at scale. Qualified activities include performing CAD modeling for new joint replacement implants, designing innovative programmable logic controllers, compiling source code for device firmware, and conducting destructive testing to validate the fatigue limits of new biocompatible materials.
The Tax Court case Intermountain Electronics serves as highly relevant guidance for Kalamazoo’s medical device contract manufacturers. The court acknowledged that process improvements occurring directly on the shop floor—not just in a pristine R&D laboratory—can constitute qualified research, provided rigorous documentation demonstrates a systematic evaluation of alternatives. For example, designing custom jigs, fixtures, and unique computer numerical control (CNC) programs to machine a complex titanium implant qualifies under the permitted purpose of improving process performance. Furthermore, as demonstrated in case studies of incremental product improvement, developing a second-generation surgical instrument with upgraded electronics or ergonomics is explicitly eligible; the invention does not need to be revolutionary to qualify, provided technical uncertainty existed at the outset.
Michigan State Credit Application: The Stryker supply chain involves numerous specialized, mid-market engineering and contract manufacturing firms located within Kalamazoo. If a local precision machining firm has 150 employees, it qualifies under Michigan’s “small business” tier. This classification provides a massive strategic advantage. The firm can claim a 3% credit on QREs up to their base amount, and an aggressive 15% credit on QREs exceeding the base amount, capped at $250,000. The ability to claim this substantial state credit, decoupled from the federal Section 174 amortization penalties, provides vital, non-dilutive capital to reinvest in automated robotics and advanced tooling.
Flavor Chemistry and Food Science (The Legacy of A.M. Todd and Kalsec)
Historical Development in Kalamazoo The highly advanced flavor chemistry and botanical extraction industry in Kalamazoo traces its origins to the 1860s and the visionary efforts of Albert M. Todd, known internationally as the “Peppermint King”. Kalamazoo’s surrounding muckland, historically formed by glacial retreat, was highly organic and retained water perfectly, making it ideal for the cultivation of specialized crops. Todd, possessing a boyhood interest in mint, studied chemistry at Northwestern University and traveled extensively in Europe to study botanical cultivation.
In 1869, he returned to the region to establish the A.M. Todd Company. He purchased 2,000 acres of marshland in nearby Mentha, digging 15 miles of ditches to drain the property, ultimately creating the world’s largest mint farm of the time. Todd revolutionized the industry through scientific rigor, cultivating imported English Black Mitcham peppermint and inventing new steam distillation techniques that established global standards for “Crystal White” essential oil purity. By 1920, the Mentha region produced 98% of the nation’s mint oil, flavoring the world’s chewing gum and toothpaste.
This deep biological and chemical expertise seeded the region’s current flavor cluster. In 1958, the Todd family founded Kalsec in Kalamazoo, transitioning from raw agriculture to advanced food science. Kalsec pioneered the use of gas liquid chromatography in spice extraction, developed natural color systems from fruits and vegetables, and created advanced hop extraction technologies (such as Tetralone, which provided light-stable bitterness for beer in clear glass bottles).
Application of R&D Tax Credit Laws The food and beverage science sector is a prime, yet often overlooked, candidate for federal and state R&D tax credits. The IRS Audit Techniques Guide (ATG) for the Food and Beverage Industry explicitly states that while routine recipe tweaking for cosmetic changes is excluded, rigorous technological experimentation is highly rewarded.
Qualified activities in Kalamazoo’s flavor chemistry facilities include identifying molecular targets to isolate specific flavor compounds, formulating new natural food preservatives to extend shelf life, and improving existing product formulations to achieve precise analytical requirements regarding pH levels, brix levels, acid content, and product viscosity.
The recent Tax Court decision in George v. Commissioner (T.C. Memo. 2026-10) is of paramount importance here. In a heavily litigated case, the court formally recognized that agriculture and botanical sciences are technologically sophisticated industries involving complex biological systems and intricate chemistry. When Kalsec or similar Kalamazoo food-science companies attempt to breed disease-resistant botanicals (a challenge present since the devastating verticillium wilt fungus decimated local mint farms in the 1920s) or formulate complex natural color extracts, they are navigating profound biological uncertainties. Wages paid to enologists, food scientists, chemists, and QA technicians, as well as the substantial costs of raw botanical supplies consumed in destructive test batches and sensory evaluations, constitute massive QREs.
Furthermore, the booming craft brewing industry in the region can claim credits for experimenting with yeast cultures, wild fermentation techniques, and integrating analytical software for batch-yield monitoring, provided these activities rely on biological and chemical sciences rather than mere culinary preference.
Paper, Packaging, and Sustainability (The Legacy of “The Paper City”)
Historical Development in Kalamazoo For over a century, Kalamazoo was internationally recognized as “The Paper City”. The genesis of this massive industrial sector occurred in 1867 with the establishment of the Kalamazoo Paper Company. The industry exploded due to a perfect convergence of geographical blessings and imported human capital. The Kalamazoo River provided the immense, reliable volumes of water strictly necessary for pulp processing and mill operations, while the surrounding forests offered abundant raw timber.
Crucially, pioneers like B.F. Lyon, Noah Bryant, and Samuel Gibson relocated to Kalamazoo from East Coast papermaking hubs, bringing advanced technical knowledge and machinery. This established a robust training ground for mechanical and chemical engineers. By the 1910s, approximately half of Kalamazoo’s total workforce was employed in paper-related manufacturing, assembling the world’s largest concentration of paper mills.
While the industry faced a severe structural decline in the 1960s and 1970s due to environmental pressures to reduce pollution and heavy foreign competition, Kalamazoo successfully reinvented its paper sector around advanced packaging and sustainability. This evolution is epitomized by Graphic Packaging International (GPI), which operates a massive complex on Pitcher Street. In early 2022, GPI completed a $600 million investment to start up the “K2” papermaking line in Kalamazoo. As the first North American coated recycled board mill constructed in three decades, K2 produces over 1,500 tons per day of highly engineered 3-ply coated recycled board, designed to drastically reduce greenhouse gas emissions and cut water usage by 300 million gallons annually.
Application of R&D Tax Credit Laws The modern packaging industry faces extreme technical challenges as it engineers products to facilitate a circular economy, replacing single-use plastics and clamshells with functional, recycled paperboard. For Kalamazoo’s packaging sector, R&D involves highly complex chemical, environmental, and mechanical engineering.
Qualified activities under Section 41 include developing advanced moisture-barrier coatings for microwave and ovenable packaging, integrating complex automation robotics into the mill forming processes to increase production speed, and experimenting with recycled fiber chemistry to maintain structural strength while lowering the caliper thickness of the board.
When applying the statutory tests, massive industrial manufacturers must carefully navigate the “shrink-back” rule, an area heavily litigated in Little Sandy Coal Company, Inc. v. Commissioner. In that case, the Tax Court denied the credits because the taxpayer claimed an entire massive vessel as the business component, rather than shrinking back to the specific subcomponent where the technical uncertainty actually lay. For a facility like Graphic Packaging’s K2 mill, the entire $600 million paper machine does not qualify as an R&D expense. However, if engineers isolate a novel curtain coating module, an experimental automated winder subsystem, or a unique effluent treatment process, and systematically test alternatives to achieve operational stability, the specific engineering wages and testing supplies utilized for that subcomponent constitute valid QREs.
Michigan Treasury Compliance: A major, publicly traded packaging corporation operating in Kalamazoo must meticulously track these component-level engineering hours to comply with the IRS’s CCM Number 20214101F and the revised Form 6765. Given the $100 million state cap, they must submit their tentative claim to the Michigan Department of Treasury by the April 1, 2026 deadline (for 2025 expenses) using precise, actual QRE data derived from these subcomponent analyses. Estimated claims will be subject to strict proration and potential disallowance if audited.
Automotive Mobility and Component Manufacturing (The Legacy of Fuller and Eaton)
Historical Development in Kalamazoo While Detroit is globally recognized as the undisputed hub of automotive assembly, Kalamazoo historically carved out a massive, highly specialized niche in commercial vehicle components and heavy manufacturing. Early 20th-century companies like the Michigan Buggy Company (which attempted an automobile transition with the “Mighty Michigan” in 1909) and the Barley Motor Car Company (maker of the Roamer) anchored the city’s early metalworking sector.
This infrastructure attracted larger operations. In 1923, Morris Markin relocated the Checker Cab Manufacturing Company from Illinois to Kalamazoo. For the next sixty years, Checker Motors produced the iconic, boxy taxicabs that became a cultural symbol of New York City, while also stamping sheet-metal parts for other major auto manufacturers.
This dense ecosystem of precision machining spawned Fuller Manufacturing, an entity that developed highly advanced transmission technologies for heavy trucks. In 1958, the Eaton Corporation—a company originating from the Torbensen Gear and Axle Company founded by J.O. Eaton and Viggo Torbensen—acquired Fuller. Following the acquisition, Fuller introduced the Roadranger twin countershaft transmission, which quickly became the standard for the heavy truck industry. Building upon this deep legacy, Eaton expanded its R&D footprint in the Kalamazoo area, establishing a massive Innovation Center in nearby Galesburg. Recently, Eaton announced further investments in the region to develop intelligent power management components, electric vehicle (EV) electronics, inverters, and power distribution systems, transitioning the legacy metalworking industry into the era of electrification.
Application of R&D Tax Credit Laws Automotive and mobility component R&D is at the absolute forefront of the technological transition toward electrification and the Internet of Things (IoT). In Kalamazoo, teams at facilities like the Eaton Innovation Center conduct rigorous environmental, validation, and durability testing for power electronics, battery protection systems, and intelligent microgrids. These activities firmly satisfy the “technological in nature” and “process of experimentation” tests, relying heavily on electrical engineering, mechanical engineering, and advanced software development (including firmware programming and cybersecurity risk mitigation for connected components).
However, automotive component suppliers often perform complex research and engineering under specific contracts for larger Original Equipment Manufacturers (OEMs), introducing immense legal complexity regarding the “funded research” exclusion under IRC Section 41(d)(4)(H). The Tax Court case System Technologies—involving an engineering firm designing custom finishing systems for the automotive industry—established that the choice-of-law provisions in commercial contracts heavily influence whether research is deemed “funded”. Similarly, in Meyer, Borgman & Johnson, Inc., the 8th Circuit ruled that simply bearing the risk of cost overruns on a fixed-fee contract does not satisfy the requirement; the payment must be explicitly contingent on the success of the research itself.
To legally claim the federal and Michigan R&D credits, an automotive supplier in Kalamazoo must definitively prove through its contract structures that it retains the ultimate economic risk of failure and that it retains substantial rights to the intellectual property developed, rather than simply being paid for time and materials. If the economic risk remains with the Kalamazoo manufacturer, the wages of their engineering teams, the costs of custom test fixtures, and the massive expenses associated with destructive prototype testing for advanced EV power inverters represent enormous, fully eligible QREs that can be claimed under both federal law and Michigan’s large taxpayer tier.
Final Thoughts and Strategic Outlook
Kalamazoo, Michigan, presents a unique and highly evolved micro-economy where an extraordinarily rich history of diverse manufacturing intersects with modern, high-technology research and development. From the pioneering botanical experiments in the 19th-century mucklands to the complex biological systems engineered by modern pharmacology, and from the heavy metal-stamping lines of early cab manufacturers to the intelligent power distribution grids of tomorrow, the city continues to act as a powerful crucible of innovation.
The statutory frameworks of the United States federal R&D tax credit (IRC Section 41) and the newly re-established Michigan state R&D tax credit (PA 186 and 187 of 2024) are specifically designed to reward the precise types of rigorous, experimental activities occurring daily in Kalamazoo’s laboratories, test tracks, and manufacturing floors. However, claiming these incentives is increasingly complex. As demonstrated by the volatile landscape of IRC Section 174 amortization rules, the stringent new reporting requirements of IRS Form 6765, and heightened judicial scrutiny in cases like Phoenix Design Group and Little Sandy Coal, taxpayers must maintain meticulous contemporaneous documentation, adhere strictly to sub-component shrink-back rules, and conduct thorough legal analyses of their funded research contracts.
By successfully leveraging the uncapped federal credit alongside Michigan’s strategic, tiered state-level credit—which provides up to $2,000,000 for large employers and highly favorable 15% marginal rates for small businesses—Kalamazoo enterprises can generate significant, non-dilutive capital. This enhanced cash flow is vital for mitigating the rising costs of domestic R&E capitalization, ensuring that Southwest Michigan remains a fiercely competitive, global leader in life sciences, medical technology, sustainable packaging, and advanced mobility for decades to come.
The information in this study is current as of the date of publication, and is provided for information purposes only. Although we do our absolute best in our attempts to avoid errors, we cannot guarantee that errors are not present in this study. Please contact a Swanson Reed member of staff, or seek independent legal advice to further understand how this information applies to your circumstances.
